Brokers Offer Predictions for ALDX Q1 Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Aldeyra Therapeutics in a research note issued on Monday, November 17th. HC Wainwright analyst M. Caufield forecasts that the biotechnology company will earn ($0.15) per share for the quarter. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at $0.02 EPS, FY2028 earnings at $0.95 EPS and FY2029 earnings at $1.25 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04.

A number of other research firms have also issued reports on ALDX. BTIG Research reiterated a “buy” rating and issued a $9.00 target price on shares of Aldeyra Therapeutics in a report on Monday, November 10th. Zacks Research upgraded Aldeyra Therapeutics to a “hold” rating in a research note on Friday, August 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Aldeyra Therapeutics in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $9.50.

Aldeyra Therapeutics Stock Down 0.8%

Shares of ALDX stock opened at $4.91 on Tuesday. The firm has a 50 day moving average of $5.20 and a two-hundred day moving average of $4.47. The stock has a market capitalization of $295.40 million, a PE ratio of -5.78 and a beta of 0.79. Aldeyra Therapeutics has a 52 week low of $1.14 and a 52 week high of $7.20.

Institutional Investors Weigh In On Aldeyra Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio acquired a new stake in shares of Aldeyra Therapeutics in the 2nd quarter valued at about $25,000. Inspirion Wealth Advisors LLC bought a new stake in Aldeyra Therapeutics during the 2nd quarter valued at $38,000. BNP Paribas Financial Markets lifted its holdings in Aldeyra Therapeutics by 36.9% in the third quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 2,859 shares during the period. King Wealth Management Group bought a new position in shares of Aldeyra Therapeutics in the second quarter valued at approximately $46,000. Finally, Inscription Capital LLC bought a new position in Aldeyra Therapeutics during the 3rd quarter valued at $66,000. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.